Min H. Kang
Impact in
- Oncology top 2%
- Cancer-related Molecular Pathways
- Molecular Biology top 2%
- Histone Deacetylase Inhibitors Research
- Cell death mechanisms and regulation
- Protein Degradation and Inhibitors
- Cancer therapeutics and mechanisms
- Epigenetics and DNA Methylation
Papers in
-
- Retinoids in leukemia and cellular processes 13
- Cancer therapeutics and mechanisms 11
- Cell death mechanisms and regulation 10
- Sphingolipid Metabolism and Signaling 6
- PI3K/AKT/mTOR signaling in cancer 5
- Neurology 17
- Neuroblastoma Research and Treatments 16
- Co-authors
- C. Patrick Reynolds (89 shared papers)Malcolm Anders Smith (56 shared papers)Peter John Houghton (53 shared papers)John M. Maris (52 shared papers)Richard B. Lock (48 shared papers)Edward Anders Kolb (49 shared papers)Richard Greg Gorlick (50 shared papers)Stephen Thomas Keir (49 shared papers)
- Journals
- Pediatric Blood & Cancer (54 papers)Clinical Cancer Research (8 papers)Cancer Chemotherapy and Pharmacology (3 papers)Molecular Cancer Therapeutics (3 papers)Blood (3 papers)
- Partner nations
- United StatesAustraliaSouth Korea
In The Last Decade
Min H. Kang
122 papers receiving 5.5k citations
Min H. Kang's Hit Papers
Peers
Comparison fields: 5 of 121
- Oncology 1.6k
- Molecular Biology 3.4k
- Cancer Research 633
- Neurology 615
- Genetics 272
Countries citing papers authored by Min H. Kang
This map shows the geographic impact of Min H. Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Min H. Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Min H. Kang more than expected).
Fields of papers citing papers by Min H. Kang
This network shows the impact of papers produced by Min H. Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Min H. Kang. The network helps show where Min H. Kang may publish in the future.
Co-authors
The 25 scholars most cited alongside Min H. Kang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 124 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy Hit paper breakdown → | 2009 | 877 |
| 2 | Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. | 2002 | 463 |
| 3 | 2010 | 199 | |
| 4 | 2002 | 183 | |
| 5 | 2019 | 156 | |
| 6 | 2019 | 146 | |
| 7 | 2007 | 132 | |
| 8 | 2008 | 109 | |
| 9 | 2014 | 106 | |
| 10 | 2014 | 106 | |
| 11 | 2010 | 94 | |
| 12 | 2015 | 92 | |
| 13 | 2010 | 88 | |
| 14 | 2011 | 86 | |
| 15 | 2010 | 85 | |
| 16 | 2010 | 85 | |
| 17 | 2016 | 81 | |
| 18 | 2015 | 75 | |
| 19 | 2011 | 74 | |
| 20 | 2013 | 73 |
About Min H. Kang
Min H. Kang is a scholar working on Molecular Biology, Neurology, Oncology, Cancer Research and Hematology, having authored 124 papers that have together received 5.6k indexed citations. Recurring topics across this work include Neuroblastoma Research and Treatments (16 papers), Retinoids in leukemia and cellular processes (13 papers), Cancer therapeutics and mechanisms (11 papers), Cell death mechanisms and regulation (10 papers), Acute Lymphoblastic Leukemia research (9 papers), Sphingolipid Metabolism and Signaling (6 papers), Cancer-related Molecular Pathways (5 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). The work is most often cited by research in Oncology (1.6k citations), Molecular Biology (3.4k citations), Cancer Research (633 citations), Neurology (615 citations) and Genetics (272 citations). Min H. Kang has collaborated with scholars based in United States, Australia and South Korea. Frequent co-authors include C. Patrick Reynolds, Malcolm Anders Smith, Peter John Houghton, John M. Maris, Richard B. Lock, Edward Anders Kolb, Richard Greg Gorlick, Stephen Thomas Keir, Hernán Carol and Ismail S. Mohiuddin. Their work appears in journals such as Pediatric Blood & Cancer, Clinical Cancer Research, Cancer Chemotherapy and Pharmacology, Molecular Cancer Therapeutics and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.